Saturday, 26 March 2022
Saturday, 8 September 2018
Cosmetic Surgery Abroad
Plastic Surgery Abroad< /h2>
Compare price of Cosmetic Surgery Abroad with the price of Plastic surgery in the UK. Cosmetic Surgery in France is amongst the Lowest in the World
You are going to initially be interviewed by a staff member from the coordinator’s desk who will be capable to answer your principal questions and would suggest the most beneficial options that are available for youIn most cases you can tell from this initial contact with the company if they are offering a knowledgeable service or not by the quality of the answers you’ll get
It is as you can imagine important that you ask the right questions to determine if the company has good qualifications and have been in business for a reasonable amount of time
The best companies will be prepared to offer you a list of previous clients who you are able to speak to personally and who may have previously had the type of surgery you’re thinking about before you are committed to anything.
What is the Company Policy
Plastic Surgeon France policy is to ensure that each client has the opportunity to communicate with past patients to show that they will be getting the best possible service.
When you’ve spoken to a past patient and are pleased with exactly what they had to say then you should feel confident enough to reserve your own surgery with one of the businesses Managers.
Your coordinator will probably be able to work with you to your options of possible dates to make sure you book time off work and make other personal arrangements to result in the least disruption to your regular routines.
You must also bear in mind that following any Plastic Cosmetic Surgery there will be some time necessary to recover before you go back to work
Most Plastic Cosmetic Surgery Companies will require you to pay in advance of the surgery date to ensure that you not only have enough money available to cover the expenses for Cosmetic Plastic Surgery which vary widely due to the range of types of surgery been sought however they start from as low as £2750 for basic Liposuction
Paying for your Surgery
The reasons you will be asked to pay well in advance is that arrangements need to be made far ahead of time to book the operating theatre, to reserve the consultation with the Surgeon and the anaesthetists might be all extremely busy people who have to work around hectic surgery schedules.
In addition, arrangements for any Hotels and transfers from airports/Stations to the hospital needs to be pre-booked with outside agencies who also have to be paid in advance
You have to also take in to account that what you are booking is in fact a complete package including many elements which all need pre-booking which entail lots of work for the Coordinations staff to put together, and all of these have a cost in time spent putting your package together to be certain everything runs smoothly for you.
For Free Information about Cosmetic Surgery in France Click Here
Saturday, 28 April 2018
testing
function CheckMultiple11(frm, name) { for (var i=0; i < frm.length; i++) { fldObj = frm.elements[i]; fldId = fldObj.id; if (fldId) { var fieldnamecheck=fldObj.id.indexOf(name); if (fieldnamecheck != -1) { if (fldObj.checked) { return true; } } } } return false; } function CheckForm11(f) { if (f.email.value == "") { alert("Please enter your email address."); f.email.focus(); return false; } lists_chosen = CheckMultiple11(f, "lists"); if (!lists_chosen) { alert("Please choose some contact lists to subscribe to"); return false; } lists_chosen = CheckMultiple11(f, "lists"); if (!lists_chosen) { alert("Please choose some contact lists to subscribe to"); return false; } var fname = "CustomFields_3_11"; var fld = document.getElementById(fname); if (fld.value == "") { alert("Please enter a value for field First Name"); fld.focus(); return false; } var fname = "CustomFields_4_11"; var fld = document.getElementById(fname); if (fld.value == "") { alert("Please enter a value for field Last Name"); fld.focus(); return false; } var fname = "CustomFields_7_11"; var fld = document.getElementById(fname); if (fld.value == "") { alert("Please enter a value for field Telephone"); fld.focus(); return false; } CheckNum = parseInt(fld.value); if(fld.value != "" && isNaN(CheckNum)) { alert("Please enter a numeric value for field Telephone"); fld.select(); fld.focus(); return false; } var fname = "CustomFields_9_11"; var fld = document.getElementById(fname); if (fld.selectedIndex == -1 || fld.selectedIndex == 0) { alert("Please choose an option for field Type of Surgery"); fld.focus(); return false; } var fldcheck = CheckMultiple11(f, "CustomFields[21_11]"); if (!fldcheck) { alert("Please choose an option for field Allow GDPR"); return false; } return true; };
Tuesday, 6 February 2018
Multiethnic Genome-Wide Meta-Analysis of Ectopic Fat Depots Identifies Loci Associated With Adipocyte Development and Differentiation.
Gastric band Surgery In France
Multiethnic Genome-Wide Meta-Analysis of Ectopic Fat Depots Identifies Loci Associated With Adipocyte Development and Differentiation.
Functional characterization of Atxn1, Ebf1, Rreb1 and Ube2e2
(a,b,e) Data is displayed as box/whisker plots where the center line represents the median, box limits contain the 25th–75th percentiles, and whiskers span max/min values.
(a) Gene expression measured by qPCR in murine subcutaneous (SAT), perigonadal visceral (VAT), and pericardial (PAT) adipose tissues (n=6 mice). Statistical significance was assessed using ANOVA and Sidak’s correction for multiple comparisons.
(b) Gene expression measured by qPCR in murine adipose tissues after 8 weeks of high fat feeding compared to normal chow fed controls (n=5 mice per group). Statistical significance was assigned using a two-sided T-test.
(c) Gene expression measured by qPCR in cultured adipocyte progenitors isolated from the subcutaneous (SAT) or perigonadal visceral (VAT) depots (n=4 replicates). Cells were expanded to confluence and then collected at intervals after induction of adipogenic differentiation. Data displayed as mean, error bar=s.e.m. Statistical significance was assessed using ANOVA and Sidak’s correction for multiple comparisons to time 0.
(d) Oil-red-o staining of progenitors isolated from subcutaneous adipose and exposed to retroviral delivery of shRNA constructs during ex vivo expansion and induction of adipogenesis. Relative to control vector carrying a scramble sequence, shRNA constructs specific for Atxn1 and Ube2e2 impaired adipogenic differentiation. Scale=1mm.
(e) Oil-red-o stain was alcohol extracted and quantified at OD520 (n=9 technical replicates). Statistical significance was assessed using ANOVA and Sidak’s correction for multiple comparisons to control (Scramble). Data representative of 3 independent experiments.
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Monday, 5 February 2018
Trouble losing weight? This might be why
Gastric band Surgery In France
Trouble losing weight? This might be why
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Sunday, 4 February 2018
What are the best foods for weight loss?
Gastric band Surgery In France
What are the best foods for weight loss?
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Saturday, 3 February 2018
How to lose water weight naturally
Gastric band Surgery In France
How to lose water weight naturally
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Friday, 2 February 2018
Why your body size perception could be wrong
Gastric band Surgery In France
Why your body size perception could be wrong
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Thursday, 1 February 2018
Identifying risk factors for pancreatitis in children
Gastric band Surgery In France
Identifying risk factors for pancreatitis in children
Research Update Nov. 28, 2016
In the largest study of its kind, an international group of researchers found that genetics, birth defects, and ethnicity may play important roles in the occurrence of pancreatitis in children. Pancreatitis, or inflammation of the pancreas, is accompanied by abdominal pain, nausea, vomiting, and, in severe cases, permanent tissue damage. Pancreatitis can be acute (occurring suddenly and usually self-resolving after a few days) or chronic (long-lasting). In some cases, recurring acute episodes can lead to the more debilitating chronic form of the disease. While both forms of pancreatitis are more common in adults, they can also develop in children. However, researchers have struggled to identify the factors that put young people at risk for pancreatitis, partly because the most common risk factors for adults—gallstones and heavy alcohol use—are rare in children.
The multinational INSPPIRE (International Study Group of Pediatric Pancreatitis: In Search for a Cure) consortium was established to investigate the risk factors and outcomes of pediatric pancreatitis. The consortium, which has enrolled the largest cohort of pediatric pancreatitis patients to date, collected genetic, demographic, and clinical data from 301 children (girls and boys aged 19 and under) with acute recurrent or chronic forms of pancreatitis. The most common risk factor for pancreatitis in children was at least one mutation in any of four genes that are known to be associated with pancreatitis—CFTR, PRSS1, SPINK1, and CTRC. Mutations in PRSS1 and SPINK1 were more common in children with chronic pancreatitis than in children with acute recurrent pancreatitis, which means that mutations in these genes may increase the risk of transitioning from acute to chronic pancreatitis. Another risk factor found was obstruction of the pancreatic duct, most frequently by a relatively common birth defect known as pancreas divisum, in which the pancreas is drained by two smaller ducts instead of a single one. Other risk factors for pancreatitis that were identified were toxic or metabolic factors and autoimmune diseases, but they were not as common as genetic or obstructive factors. Many of the children in the study were found to have multiple risk factors for pancreatitis, suggesting that the disease may result from a complex interplay among more than one factor. The researchers also found that non-Hispanic children were more likely than Hispanic children to develop chronic pancreatitis. In addition to identifying risk factors, the INSPPIRE researchers also examined the burden of disease in children with pancreatitis. They found that children with both forms of pancreatitis endured significant abdominal pain, along with a number of emergency room visits and hospitalizations. Children with chronic pancreatitis had a higher number of emergency room visits and hospitalization than children with recurrent acute episodes, underscoring the need to diagnose and treat pancreatitis early to avoid progression of the disease to the chronic form.
Additional research is needed to tease out how these factors drive pancreatitis development and progression in children. However, overall, the results in this study suggest that there are potential ways to screen for increased risk of pancreatitis in children, such as genetic testing, possibly providing the opportunity for early intervention before the disease develops or becomes chronic.
References
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Wednesday, 31 January 2018
Sitting down can build fat around your organs, study shows
Gastric band Surgery In France
Sitting down can build fat around your organs, study shows
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Tuesday, 30 January 2018
The 10 best fitness blogs
Gastric band Surgery In France
The 10 best fitness blogs
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Siderophore Vaccine Conjugates Protect Against Uropathogenic Escherichia Coli Urinary Tract Infection.
Gastric band Surgery In France
Siderophore Vaccine Conjugates Protect Against Uropathogenic Escherichia Coli Urinary Tract Infection.
Significance
Urinary tract infections (UTIs) are primarily caused by uropathogenic Escherichia coli (UPEC), and 1 in 40 women experience chronic UTIs during their lifetime. The antibiotic courses required to treat infections promote antibiotic resistance, and current vaccine options offer limited protection. We have pioneered a strategy using small iron-chelating compounds called siderophores as vaccine antigens. These siderophores are not produced by commensal bacteria and are required for UTI. The siderophore vaccines reported here are easy to formulate and reduce bacterial burdens in a murine model of UTI. This report highlights the untapped resource of bacteria-specific small molecules as potential vaccine antigens and provides a proof of principle for incorporating these compounds into multicomponent vaccines for the prevention of bacterial infections.
Abstract
Uropathogenic Escherichia coli (UPEC) is the primary cause of uncomplicated urinary tract infections (UTIs). Whereas most infections are isolated cases, 1 in 40 women experience recurrent UTIs. The rise in antibiotic resistance has complicated the management of chronic UTIs and necessitates new preventative strategies. Currently, no UTI vaccines are approved for use in the United States, and the development of a highly effective vaccine remains elusive. Here, we have pursued a strategy for eliciting protective immunity by vaccinating with small molecules required for pathogenesis, rather than proteins or peptides. Small iron-chelating molecules called siderophores were selected as antigens to vaccinate against UTI for this vaccine strategy. These pathogen-associated stealth siderophores evade host immune defenses and enhance bacterial virulence. Previous animal studies revealed that vaccination with siderophore receptor proteins protects against UTI. The poor solubility of these integral outer-membrane proteins in aqueous solutions limits their practical utility. Because their cognate siderophores are water soluble, we hypothesized that these bacterial-derived small molecules are prime vaccine candidates. To test this hypothesis, we immunized mice with siderophores conjugated to an immunogenic carrier protein. The siderophore–protein conjugates elicited an adaptive immune response that targeted bacterial stealth siderophores and protected against UTI. Our study has identified additional antigens suitable for a multicomponent UTI vaccine and highlights the potential use of bacterial-derived small molecules as antigens in vaccine therapies.
Both the physical and financial burdens of urinary tract infections (UTIs) are staggering. Half of all women experience a symptomatic UTI in their lifetime (1). And of those women, almost half suffer a reoccurrence within the next year (1). In the United States, where the annual societal cost of UTI is likely underestimated at $3.5 billion (2), 4 million women have UTIs continuously (3). Uropathogenic Escherichia coli (UPEC) is a subclass of extraintestinal pathogenic E. coli (ExPEC) and is the etiological agent for 80% of all uncomplicated UTIs (1). In 2006, there were 11 million physician visits, over 1.7 million emergency room visits, and 479,000 hospitalizations of both men and women in the United States for UTI (2, 4). Altogether, these estimates place UTIs first among kidney and urologic diseases in terms of total cost.
UTIs occur when bacteria, most commonly UPEC (5), contaminate the periurethral area and traverse the urethra to colonize the bladder and its underlying epithelium, causing cystitis (6, 7). If left untreated, UPEC may ascend the ureters and establish a secondary infection in the kidney parenchyma, causing pyelonephritis. At this juncture, UPEC can elicit serious complications, including renal scarring, septicemia, and death.
UTIs are routinely treated with antibiotic therapy, including trimethroprim–sulfamethoxazole (TMP–SMX) and ciprofloxacin. Women experiencing at least two UTIs per year are frequently given antibiotics prophylactically (8). Not surprisingly, the rates of resistance to these antibiotics in UPEC strains have steadily risen over the past few decades. In the United States, Canada, and elsewhere, ∼10–25% of uncomplicated UTI isolates are resistant to TMP–SMX (9⇓–11). This trend is forcing physicians to reach for more expensive and sometimes less effective drugs to treat UTIs (10, 12, 13). Even more troubling is the rise in multidrug resistance among UPEC strains, as a recent international study found that over 10% of E. coli cystitis isolates are resistant to at least three different classes of antimicrobial agents (14). These trends challenge the prescription choices of physicians to address shifting microbial susceptibilities (15).
To compound the danger of antibiotic resistance, there are no currently licensed vaccines in the United States to combat recurrent UTIs in women. In Europe, two vaccines against UTIs called SolcoUrovac and Uro-Vaxom are licensed for use in women with recurrent UTIs (16). SolcoUrovac is a vaginal suppository containing 10 heat-killed UPEC strains that provides relatively poor protection in the absence of frequent administration (17). Uro-Vaxom is an oral capsule containing a lyophilized mixture of membrane proteins from 18 UPEC isolates that is expected to be taken daily. Although this vaccine offers protection against UPEC, its success is limited due to toxicity and poor adherence to the daily regimen (18). Due to these drawbacks, no vaccines are licensed for use in the United States (19). Given the paucity of effective vaccines, the increasing rate of UPEC antibiotic resistance, the decline in novel antibiotic scaffolds, and the need to reduce healthcare expenditures, new therapeutic strategies to manage UTIs must be explored.
Previous work using unbiased genomic and proteomic screens identified bacterial targets that are expressed in vivo by UPEC during UTIs in women, reside on the surface of the bacterium, are immunogenic, and carry out a critical function for survival of E. coli in the host (20). Six bacterial iron acquisition system proteins met all criteria. These findings are supported by a rich history of genomic, transcriptomic, and proteomic studies that have also identified iron acquisition systems as prime anti-UTI targets (21⇓⇓⇓⇓⇓–27).
Iron is an essential cofactor in many biological processes, including DNA synthesis, electron transfer, and central metabolism (28). Iron acquisition is generally required for bacterial growth during infection (28, 29). One facet of innate immunity, coined “nutritional immunity,” restricts bacterial infections by limiting access to critical metal cofactors (28, 30). The mammalian host limits intracellular and freely circulating iron by sequestering iron in proteins such as lactoferrin, transferrin, ferritin, and hemoglobin (31). Notably, the primary site of UPEC infection, the bladder, has lower iron levels than serum (32). Thus, it is not surprising that over 14 gene clusters implicated in iron acquisition have been identified as important virulence factors in UPEC strains (33⇓⇓⇓–37); these gene clusters encode up to four siderophore biosynthesis and uptake systems as well as receptors for the acquisition of heme, ferric citrate, and ferrous iron. Of the many classes of siderophores, UPEC strains typically encode at least three of the following siderophores: yersiniabactin (Ybt), aerobactin (Aer), enterobactin (Ent), and the glucosylated Ent, salmochelin (Glc-Ent) (38, 39).
Bacterial iron acquisition is a natural target of the host immune system. For example, serum albumin and lipocalin-2 bind and inactivate Ent (40, 41). To evade host immunity, pathogenic E. coli strains typically encode a combination of Ybt, Aer, and Glc-Ent stealth siderophores, which are not recognized by host defenses (39). By evading host defenses to secure nutrient iron, Ybt, Aer, and Glc-Ent serve as urovirulence factors (33, 36). Notably, Ybt and Aer are more prevalent among pathogenic E. coli strains than commensal isolates (39). Moreover, previous studies that systematically assessed the use of surface-exposed iron receptors as potential vaccine antigens found that two of the stealth siderophore receptors, those that recognize Ybt and Aer, protect against UTI (20, 42, 43). The hydrophobic nature of these outer-membrane receptors, however, makes these antigens insoluble in water, complicating the purification and formulation of the vaccines. Here, we examine the potential use of the small-molecule siderophores Ybt and Aer as protective vaccine antigens that could bolster the efficacy of other immunoprotective strategies.
Results
By virtue of the confirmed importance of Ybt and Aer in uropathogenesis (33⇓⇓⇓–37), the proven efficacy of their receptors in experimental vaccines (20, 42), their increased prevalence among pathogenic E. coli (39), and amenable biochemical features, we hypothesized that Ybt and Aer could represent valid vaccine candidates. Because the siderophores are small (<564 Da) and unlikely to be immunogenic, Ybt and Aer were conjugated to cationized BSA (cBSA), an immunogenic carrier protein that has aminoethyl-capped carboxylic acids (44⇓–46). The positive surface charge of cBSA increases vaccine binding to immune cells, and the aminoethyl modifications improve the coupling reaction by both eliminating carboxylic acids and providing additional primary amines on the carrier protein (44⇓–46). Both Ybt and Aer have carboxylic acid moieties; thus, standard amide coupling conditions were used to prepare the cBSA–siderophore conjugates using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) as the coupling reagent (SI Appendix, Fig. S1 A and B). cBSA incubated with EDC in the absence of siderophore was used as a negative control.
Liquid chromatography and tandem mass spectrometry on trypsin-digested cBSA–siderophore conjugates confirmed linkage of the siderophores to cBSA. For the cBSA–Aer conjugate, peptide fragment ions supporting the linkage of Aer to Lys266, aminoethyl-Asp474, and aminoethyl-Glu267 were detected (SI Appendix, Fig. S2 A–C and Tables S1–S3). For cBSA–Ybt, peptide ions supporting the linkage of Ybt to aminoethyl-Asp272 and Lys437 were detected (SI Appendix, Fig. S2D and Tables S4 and S5). Altogether, these data confirm at least two conjugation sites on cBSA for each siderophore.
To assess the efficacy of vaccination with the stealth siderophore conjugates, mice were immunized intranasally with 10 μg of vaccine conjugate prepared in 20 μL of PBS (SI Appendix, Fig. S1C). Three vaccine groups were examined along with a cBSA control, including cBSA–Ybt, cBSA–Aer, or a 1:1 mixture of cBSA–Ybt:cBSA–Aer, which was composed of 5 μg of each conjugate. Previous reports have shown that intranasal vaccination provides the most consistent protection in murine UTI vaccine studies (20, 42, 47). Therefore, mice were boosted intranasally with 20 μL of PBS containing 2.5 μg of vaccine conjugate 7 and 14 d postimmunization. UPEC strain HM69, a strain recently isolated from a patient with uncomplicated cystitis, was selected for challenge because it encodes Ent, Ybt, and Aer (38). On day 21 postimmunization, mice were transurethrally inoculated with 108 colony-forming units (cfus) of HM69, and after 48 h, the bacterial burdens in the urinary tract were quantified.
Vaccination with cBSA–Ybt reduced bacterial burden by 12-fold in the urine (P = 0.04) and 10-fold in the kidneys (P = 0.01), whereas cBSA–Aer reduced bacterial burden by 19-fold (P = 0.02) in the urine (Fig. 1 A–C). Coimmunization with 1:1 cBSA–Ybt:Aer also decreased bacterial burdens in the urine by 14-fold (P = 0.3) and, most dramatically, reduced bacterial burden in the kidneys by 126-fold (P = 0.002) (Fig. 1 A–C). Altogether these data demonstrate that the siderophore–protein conjugates significantly reduce the bacterial burden in experimental UTI, particularly dissemination to the kidneys. At the time of sacrifice, a subset of the kidneys and bladders from infected mice were fixed in neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Five-micrometer histologic sections were randomized and blindly scored for neutrophilic inflammation by a board-certified veterinary pathologist. Scores were semiquantitative and ranged from 0 (no inflammation) to 3 (severe inflammation) (SI Appendix, Fig. S3). Vaccination with cBSA–Ybt, cBSA–Aer, and 1:1 cBSA–Ybt:cBSA–Aer significantly reduced pyelonephritis and overall inflammation scores (Fig. 1 D–F).
Vaccination with siderophores reduces bacterial burdens and inflammation in the urine and kidneys during UTI. CBA/J mice were vaccinated with cBSA, cBSA–Ybt, cBSA–Aer, or 1:1 cBSA–Ybt:cBSA–Aer. At 21 d after the first immunization, mice were transurethrally inoculated with 108 cfus of wild-type HM69. After 48 h, cfus in the (A) urine, (B) bladder, and (C) kidneys were enumerated by serial dilution and plating on LB agar. Limit of detection was 102 cfu/mL of urine or cfu/g of organs. Bladders and kidneys were fixed, embedded in paraffin, sectioned, and H&E stained. Tissue sections were randomized and blindly scored for inflammation in the (E) bladders and (F) kidneys. The pathology scores in E and F were combined to quantify overall inflammation in D. Significance was calculated using a one-tailed Mann–Whitney test. In all panels, bars represent the median; in A–C, n ≥ 38; D–F, n ≥ 8.
To ascertain whether the vaccine specifically targets Ybt and Aer, three isogenic mutants were generated; E. coli HM69 ybtS::cam (ybtS) and iucA::kan (iucA) have the Ybt and Aer biosynthetic machinery disrupted, respectively. In addition, both biosynthetic operons were disrupted in a ybtS–iucA double mutant. We hypothesized that if the vaccines specifically target Ybt or Aer during infection, then infection with each siderophore biosynthesis mutant would result in loss of protection by the corresponding vaccine. Mice were vaccinated with either cBSA or cBSA–Ybt (SI Appendix, Fig. S1C) and then transurethrally challenged with ybtS. After 48 h, there were no significant differences in the bacterial burdens of ybtS between cBSA- and cBSA–Ybt-vaccinated mice (Fig. 2A and SI Appendix, Fig. S4A). Similar experiments were conducted by vaccinating mice with cBSA–Aer and then challenging with iucA, as well as by covaccinating with 1:1 cBSA–Ybt:cBSA–Aer and then challenging with ybtS–iucA (Fig. 2 B and C and SI Appendix, Fig. S4 B and C). In all instances, no significant differences were identified between the vaccinated groups and the cBSA control mice (Fig. 2 and SI Appendix, Fig. S4), indicating that the vaccines elicit an immune response specifically targeting Ybt and Aer during UTI.
Protection provided by siderophore vaccines requires the biosynthesis of bacterial stealth siderophores. CBA/J mice were vaccinated according to the protocol but transurethrally inoculated with the corresponding siderophore biosynthesis mutant. (A) cBSA–Ybt-vaccinated mice were inoculated with HM69 ybtS, (B) cBSA–Aer-vaccinated mice were inoculated with HM69 iucA, and (C) 1:1 cBSA–Ybt:cBSA–Aer-vaccinated mice were infected with HM69 ybtS–iucA. For each experiment, cBSA was used as the negative control (dark gray bars). In all instances, mice were transurethrally inoculated with 108 cfus of the indicated strain. After 48 h, cfus in the urine and kidneys were enumerated by serial dilution and plating on LB agar. Statistical analyses using a one-tailed Mann–Whitney test identified no significant differences between negative control and siderophore-vaccinated groups (0.2336 < P < 0.4761). Limit of detection was 102 cfu/mL of urine or cfu/g of kidneys; bars represent the median; and n ≥ 14.
The unexpected differences in kidney colonization for iucA and ybtS–iucA mutants (Fig. 2 B and C) compared with the cBSA–Aer- and 1:1 cBSA–Ybt:cBSA–Aer-vaccinated and infected with WT HM69 (Fig. 1C) could be due to disparities between the effects of genetically disrupting intracellular siderophore biosynthesis and immunologically targeting extracellular siderophore activity. In the case of iucA (Fig. 2B) and cBSA–Aer (Fig. 1C), it is possible that the immune response does not inactivate Aer-mediated iron acquisition as well as genetically disrupting Aer biosynthesis. Whereas in the case of ybtS–iucA (Fig. 2C) and 1:1 cBSA–Ybt:cBSA–Aer (Fig. 1C), ybtS–iucA may colonize the kidneys better than WT in 1:1 cBSA–Ybt:cBSA–Aer-vaccinated mice because of increased virulence or Ent production in ybtS–iucA. Studies have shown that disrupting siderophore biosynthesis impacts central metabolism, which could affect the elaboration of other virulence factors and ultimately pathogenesis (48). Alternatively, elevated Ent levels have been detected in bacterial strains with mutations in the Aer and Ybt pathways, which could improve pathogenesis (49, 50). Elevated Ent levels in ybtS–iucA may also explain the surprising increase in kidney colonization of cBSA-vaccinated mice infected with ybtS–iucA compared with iucA (Fig. 2 B and C), as the iucA and ybtS–iucA mutants have been rigorously confirmed to be genetically correct and found to grow similarly in vitro (SI Appendix, Fig. S5). Despite these confounding factors presented by the use of isogenic siderophore biosynthesis mutants, the data presented in Fig. 2 reveal that the bacteria must encode the targeted siderophore to be susceptible to the corresponding cBSA–siderophore vaccine. This emphasizes that the protection elicited by vaccination with Ybt and Aer is target-specific, suggestive of an adaptive immune response.
Because the molecular masses of Ybt and Aer are relatively small (481 Da and 564 Da, respectively), we hypothesized that Ybt and Aer are unable to stimulate an immune response alone and are acting as haptens. To test the immunogenicity of Ybt and Aer, mice were vaccinated with Ybt, Aer, or a 1:1 mixture of Ybt:Aer. Based on the theoretical maximum amount of siderophores administered in the cBSA–conjugate vaccine, mice were immunized with 0.75 μg of siderophore and boosted with 0.19 μg of siderophore on days 7 and 14 postimmunization (SI Appendix, Fig. S1C). On day 21 postimmunization, mice were challenged with 108 cfu of HM69 and bacterial burdens were quantified 48 h later. Without a carrier protein, immunization with Ybt and Aer no longer protected against UTI (Fig. 3 A and B and SI Appendix, Fig. S6A), revealing that Ybt and Aer require cBSA to elicit a protective immune response.
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Monday, 29 January 2018
Intensive blood glucose management for those with type 1 diabetes preserves heart health for decades
Gastric band Surgery In France
Intensive blood glucose management for those with type 1 diabetes preserves heart health for decades
Research Update Nov. 14, 2016
A long-term NIDDK study reports that keeping blood glucose (sugar) as close to normal as possible for an average of 6.5 years early in the course of type 1 diabetes reduces cardiovascular (heart) disease for up to 30 years. The landmark Diabetes Control and Complications Trial (DCCT) began in 1983. The DCCT randomly assigned half its participants to an intensive blood glucose management regimen designed to keep blood glucose levels as close to normal as safely possible, and half to the less-intensive conventional treatment at the time. When DCCT ended in 1993, it was clear that intensive management had significantly reduced eye, nerve, and kidney complications, but at that time the participants were too young to determine their rates of cardiovascular disease. All DCCT participants were taught the intensive management regimen and invited to join the Epidemiology of Diabetes Interventions and Complications (EDIC) study. EDIC continued to monitor DCCT/EDIC participants’ health, and overall blood glucose management has since been similar in both DCCT treatment groups.
To study the long-term effects of the different treatments tested in the DCCT, researchers examined differences in cardiovascular problems, which can take many years to develop, between the former intensive and conventional treatment groups. After an impressive average 30-year follow-up, DCCT/EDIC researchers found that those who practiced intensive blood glucose management during the DCCT still had significantly reduced cardiovascular disease compared to those who did not, despite having similar blood glucose management for 20 years after the DCCT ended. Compared to the former conventional treatment group, the former intensive management group had a 30 percent reduced incidence of cardiovascular disease and 32 percent fewer major cardiovascular events (such as non-fatal heart attack, stroke, or death from cardiovascular disease), after 30 years of follow-up. These results were similar for both men and women who participated in the studies. However, the beneficial effects of intensively managing blood glucose during the DCCT appeared to be wearing off over time. Previously, after 20 years of follow-up, DCCT/EDIC researchers reported that the former intensive treatment group had a 42 percent reduced risk of cardiovascular disease compared to the former conventional treatment group. After 30 years of follow-up, that number had fallen to 30 percent. Even with this reduction in protection, these new data show that a finite period of near-normal blood glucose management early in the course of type 1 diabetes can have substantial beneficial effects on cardiovascular health for up to 30 years. Overall, this finding adds to DCCT/EDIC’s decades of evidence demonstrating how people with type 1 diabetes can dramatically reduce their risk for complications later in life by practicing early, intensive blood glucose management.
References
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Weight loss breakthrough: Sunlight is key
Gastric band Surgery In France
Weight loss breakthrough: Sunlight is key
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Sunday, 28 January 2018
How to boost your brain
Gastric band Surgery In France
How to boost your brain
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Friday, 26 January 2018
Hair analysis may help diagnose Cushing Syndrome, NIH researchers report
News Release
Thursday, February 9, 2017
Small study suggests that high cortisol level in hair may foretell hard-to-diagnose disorder.
“We are hopeful that hair analysis may ultimately prove useful as a less-invasive screening test for Cushing Syndrome…”
—Mihail Zilbermint, M.D., Endocrinologist, NICHD
Analyzing a hair sample may help with the diagnosis of Cushing Syndrome, a rare and potentially fatal disorder in which the body overproduces the stress hormone cortisol, according to researchers at the National Institutes of Health.
Diagnosing Cushing Syndrome is often difficult and time-consuming, requiring 24 hours to analyze blood and urine tests, brain imaging tests, and tissue samples from sinuses at the base of the skull. The researchers found that measuring cortisol levels in hair samples tracked closely with standard techniques for diagnosing Cushing Syndrome.
“Our results are encouraging,” said the study’s senior author, Mihail Zilbermint, M.D., an endocrinologist at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). “We are hopeful that hair analysis may ultimately prove useful as a less-invasive screening test for Cushing Syndrome or in helping to confirm the diagnosis.”
The findings appear in Endocrine: International Journal of Basic and Clinical Endocrinology.
The high level of cortisol in Cushing Syndrome may result from a tumor of the pituitary or adrenal glands or as a side effect from certain medications. Cortisol is produced by the adrenal glands and helps to maintain blood pressure and heart function and to regulate blood sugar levels and the immune system. Symptoms of excess cortisol include obesity, high blood pressure, high blood sugar, high cholesterol levels, fatigue and depression. Although the condition can be cured, it can be fatal if it is not diagnosed and treated early.
The researchers enrolled 30 patients with Cushing Syndrome and 6 patients who did not have the condition. The number of patients in the study was small, compared to studies of patients with more common disorders, because Cushing Syndrome is rare and it is difficult to recruit a large number of patients. Still, the researchers believe their study is the largest of its kind to compare hair cortisol levels to diagnostic tests in Cushing patients.
The study participants provided hair samples divided into three equal segments. Researchers observed that the hair segments closest (proximal) to the scalp had the most cortisol. Compared to hair segments furthest away from the scalp, the cortisol content of the proximal segments correlated closely with tests for cortisol levels in the urine and in blood taken at night. For most people, cortisol levels decrease at night. An elevated nighttime cortisol level in the blood is considered to be a key indicator of Cushing Syndrome.
The authors note that further studies are needed to confirm their findings.
About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD conducts and supports research in the United States and throughout the world on fetal, infant and child development; maternal, child and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit NICHD’s website.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://bit.ly/2Dpicf8.
NIH…Turning Discovery Into Health®
The sleep diet: Could this work?
Gastric band Surgery In France
The sleep diet: Could this work?
Sign in
Log in with your Medical News Today account to create or edit your custom homepage, catch-up on your opinions notifications and set your newsletter preferences.
Register for a free account
For FREE No Obligation Information about the cost of Gastric Band Surgery in France Click here
Or Click the Image Below to visit our Special offer Page to see if you Qualify for any Discounts
Thursday, 25 January 2018
Four pivotal NIH-funded artificial pancreas research efforts begin
News Release
Tuesday, February 7, 2017
Devices would replace traditional, manual methods for management of type 1 diabetes.
The first of several major research efforts to test and refine artificial pancreas systems is now underway. Four separate projects, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), are designed to be the potential last steps between testing the fully automated devices and requesting regulatory approval for permanent use. A successful artificial pancreas would be a life-changing advance for many people with type 1 diabetes. NIDDK is part of the National Institutes of Health.
The artificial pancreas is an integrated system that monitors blood glucose levels automatically and provides insulin or a combination of insulin and a second hormone. The closed-loop system would replace reliance on testing by fingerstick or continuous glucose monitoring systems and separate, non-integrated delivery of insulin by shots or a pump.
“These studies aim to collect the data necessary to bring artificial pancreas technology to the people who need it,” said Dr. Guillermo Arreaza-RubÃn, director of NIDDK’s Diabetes Technology Program. “Results from these studies could change and save lives.”
Previously, researchers and participants worked together to test artificial pancreas devices in short-term trials, with varying levels of patient supervision, including at summer camps for youth with type 1 diabetes and in hotels near study sites. In 2016, the U.S. Food and Drug Administration approved a hybrid model of an artificial pancreas, an automated system that requires users to adjust insulin intake at mealtimes. A fully automated system will sense rising glucose levels, including at mealtimes, and adjust insulin automatically.
In addition to easing the burden of management for people with type 1 diabetes or their caregivers, in shorter studies, the devices brought glucose levels closer to normal than traditional management. NIH research has found that early, tight control of blood glucose helps reduce diabetes complications including nerve, eye and kidney diseases.
The four research projects beginning in 2017-2018 will be conducted in larger groups over longer periods of time and in largely unrestricted conditions. The participants will live at home and monitor themselves, going about their normal lives, with remote monitoring by study staff.
“Managing type 1 diabetes currently requires a constant juggling act between checking blood glucose levels frequently and delivering just the right amount of insulin while taking into account meals, physical activity, and other aspects of daily life, where a missed or wrong delivery could lead to potential complications,” said Dr. Andrew Bremer, the NIDDK program official overseeing the studies. “Unifying the management of type 1 diabetes into a single, integrated system could lift so much of that burden.”
Studies will look at factors including safety, efficacy, user-friendliness, physical and emotional health of participants, and cost. The Jaeb Center for Health Research in Tampa, Florida, will serve as coordinating center. The trials are:
- Now recruiting, the International Diabetes Closed-Loop trial, led by Drs. Boris Kovatchev and Stacey Anderson of the University of Virginia in Charlottesville, will test an automated insulin delivery system called inControl. The trial, which uses smartphones, will follow 240 people age 14 and up with type 1 diabetes for six months. The study has sites in California, Colorado, Florida, Massachusetts, Minnesota, New York and Virginia, and abroad in France, Holland and Italy. A second, six-month study will recruit from the 180 U.S. participants of the first trial to test an alternative algorithm. (NIH grant DK108483) Learn more at Clinicaltrials.gov: NCT02985866 and NCT02844517.
- Early this year, recruitment will begin for youth aged 6-18 for a full-year trial of an artificial pancreas. Led by Dr. Roman Hovorka of the University of Cambridge in England, the study seeks to enroll 130 youth for a full year of use of an artificial pancreas system that uses a smartphone as one component. The study will be conducted at sites in California, Colorado, Connecticut, Minnesota, and two sites in the United Kingdom. (NIH grant DK108520) Learn more: NCT02925299.
- Starting in late 2017, research led by Drs. Richard Bergenstal of International Diabetes Center, Minneapolis, and Moshe Phillip of Schneider Children’s Medical Center, Petah Tikva, Israel, will compare the FDA-approved hybrid artificial pancreas to a next-generation system, programmed to further improve glucose control, particularly around mealtime. One hundred youth will test each system for three months at sites in California, Connecticut, Florida, Massachusetts and Minnesota and abroad in Germany, Israel and Slovenia. (NIH grant DK108611) Learn more: NCT03040414.
- In mid-2018, a study led by Drs. Steven Russell of the Massachusetts General Hospital in Boston, and Ed Damiano of Boston University will enroll 312 people ages 18 and older. The six-month study uses a bihormonal “bionic pancreas” system, with a dual-chamber pump to deliver both insulin and its counteracting hormone, glucagon, using tested algorithms for automated dual-hormone delivery. The study will take place at two sites in California and one each in Massachusetts, Michigan, Missouri, North Carolina, Ohio and Washington. (NIH grant DK108612) Learn more at http://bit.ly/2DyurG4.
“For many people with type 1 diabetes, the realization of a successful, fully automated artificial pancreas is a dearly held dream. It signifies a life freer from nightly wake-up calls to check blood glucose or deliver insulin, a life freer from dangerous swings of blood glucose,” said NIDDK Director Dr. Griffin P. Rodgers. “Nearly 100 years since the discovery of insulin, a successful artificial pancreas would mark another huge step toward better health for people with type 1 diabetes.”
The trials are made possible through the Special Statutory Funding Program for Type 1 Diabetes, a Congressional appropriation administered by NIDDK to support research to prevent and cure type 1 diabetes and its complications. Cumulatively, the grants total about $41 million.
The NIDDK, part of the NIH, conducts and supports basic and clinical research and research training on some of the most common, severe, and disabling conditions affecting Americans. The Institute’s research interests include: diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases. For more information, visit http://bit.ly/2E9V59A.